Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide vs Placebo in Active Takayasu Arteritis
NCT02981979Completed
- Sponsor
- Lindi (Jiangsu) Biotechnology
- Start
- Dec 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of leflunomide in Takayasu arteritis (TAK) (2 arms), sponsored by Lindi (Jiangsu) Biotechnology. Primary endpoint: Achievement of clinical remission at 24 weeks. Started Dec 2016; status: completed.
02
Drugs
leflunomide
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT02981979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981979.